February 28, 2017 / 1:55 PM / 9 months ago

BRIEF-Valeant sees continued pressure on dermatology volumes

Feb 28 (Reuters) - Valeant Pharmaceuticals International Inc

* Valeant says q4 was held back by pricing pressure, decline in dermatology prescriptions, egyptian currency

* Valeant reiterates August 2016 plan is to pay down $5 billion in debt within 18 months of that statement

* Valeant says has sold or agreed to sell 10 businesses to raise up to $2.7 billion to pay down debt

* Valeant sees continued pressure on dermatology volumes due to higher co-pays and managed care rebates in 2017 Further company coverage: (Reporting By Caroline Humer)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below